Interestingly, 26% of CLL patients failed to develop NAbs but had high-titer binding Abs that preferentially reacted with the S2 subunit of the SARS-CoV-2 spike. This evidence concerns the gene DDX41 and B-cell chronic lymphocytic leukemia.